poisar

Stocks · News reference

Gyre Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

Fiscal.ai

Gyre Therapeutics reported its third quarter 2026 financial results, including $32.9 million in revenue, and affirmed its full-year 2026 revenue guidance.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — GYRE THERAPEUTICS, INC. (GYRE)

    Filed: 2026-11-05 AccNo: 0001193125-26-449985 Size: 13 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits